SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 5.75% Stake in Intensity Therapeutics

Armistice Capital, LLC and Steven Boyd have disclosed a 5.75% beneficial ownership stake in Intensity Therapeutics, Inc., holding 872,547 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G Amendment No. 1 regarding their beneficial ownership in Intensity Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 872,547 shares of Intensity Therapeutics, Inc. Common Stock, representing 5.75% of the class.
• This percentage is based on 15,180,945 shares outstanding as of March 12, 2025, as reported in the Issuer's Form 10-K filed with the SEC on March 13, 2025.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the company's perceived financial health or strategic direction.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded company, indicating a significant, non-controlling equity stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.

Key Dates

Keywords

Intensity Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, equity stake